Currently out of the existing stock ratings of Daniil Gataulin, 33 are a BUY (78.57%), 9 are a HOLD (21.43%).

Daniil Gataulin

Work Performance Price Targets & Ratings Chart

Analyst Daniil Gataulin, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 18.1% that have a potential upside of 33.43% achieved within 116 days.

Daniil Gataulin’s has documented 77 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on EYPT, Eyepoint Pharmaceuticals at 06-Feb-2025.

Wall Street Analyst Daniil Gataulin

Analyst best performing recommendations are on OTLK (OUTLOOK THERAPEUTICS INC).
The best stock recommendation documented was for OTLK (OUTLOOK THERAPEUTICS INC) at 8/15/2023. The price target of $10 was fulfilled within 15 days with a profit of $21 (67.74%) receiving and performance score of 45.16.

Average potential price target upside

ADVM Adverum Biotechnologies AGTC Applied Genetic KOD Kodiak Sciences OCGN Ocugen OYST Oyster Point Pharma RGNX Regenxbio EYPT Eyepoint Pharmaceuticals FREQ Frequency Therapeutics OTLK OUTLOOK THERAPEUTICS INC FBRX Forte Biosciences

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$16

$12.06 (306.09%)

$20

3 months ago
(22-Nov-2024)

1/3 (33.33%)

$9.96 (164.90%)

292

Buy

$30

$26.06 (661.42%)

$30

3 months 3 days ago
(19-Nov-2024)

0/4 (0%)

$23.75 (380.00%)

Hold

$10

$6.06 (153.81%)

$12

3 months 17 days ago
(05-Nov-2024)

1/3 (33.33%)

$2.28 (29.53%)

81

Buy

$40

$36.06 (915.23%)

$4

7 months 4 days ago
(18-Jul-2024)

1/5 (20%)

$30.52 (321.94%)

558

Buy

$6

$4.05 (207.69%)

$4

1 years 5 months 17 days ago
(05-Sep-2023)

4/7 (57.14%)

$4.22 (237.08%)

196

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Daniil Gataulin is most bullish on?

Potential upside of $53.02 has been obtained for FBRX (FORTE BIOSCIENCES)

Which stock is Daniil Gataulin is most reserved on?

Potential downside of -$0 has been obtained for RGNX (REGENXBIO)

What Year was the first public recommendation made by Daniil Gataulin?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?